伐度司他(Vadadustat)2025年各版本的价格

Valadostat is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, used to treat anemia in patients with dialysis-dependent chronic kidney disease (CKD). It was approved in Japan in 2020 and by the US FDA in 2023.

Prices of various versions of Vadadustat in 2025

The price of Vadadustat in 2025 is affected by many factors. The following prices are for reference only.

Specifications and Prices

The original drug is produced by MEDICE in Germany. The specification is 300mg*98 tablets/box, and the price remains at around US$320. When purchasing, you need to provide a doctor's prescription and other proof to avoid purchasing uncertified products.

Recommended dose

The starting dose for adult patients is 300 mg orally daily, which needs to be swallowed whole. There is no need to make up for missed doses, and you can continue taking the medicine as originally planned the next day. During treatment, hemoglobin (Hb) needs to be monitored every 2 weeks, with a target value of ≤11g/dL. If Hb rises too fast, such as >1g/dL/2 weeks, the medication needs to be suspended and the dose adjusted to avoid the risk of thrombosis.

Patients must give priority to purchasing through regular medical institutions or cross-border platforms to ensure that the drug packaging is complete and comes with instructions.

Will Vadadustat cause side effects

Vadadustat may cause a variety of adverse reactions, most of which can be effectively controlled through monitoring and intervention.

High blood pressure and thrombosis risk

Some patients may experience elevated blood pressure and need to monitor and adjust their antihypertensive drug regimen weekly. If chest pain, difficulty breathing, or swelling of limbs occurs, it indicates thrombosis, and you need to stop taking the medicine immediately and seek medical treatment. Minor risks of blood clots can be prevented with low-dose aspirin, but use must be evaluated by a doctor.

Hepatotoxicity management

Some patients may experience elevated ALT/AST. Liver function needs to be tested monthly for the first 6 months of treatment. If ALT/AST is >3 times the normal value or accompanied by jaundice, the drug needs to be permanently discontinued and hepatoprotective treatment required. Mild increases can maintain the dose and increase the frequency of monitoring.

The incidence of diarrhea is high, which can be alleviated by dietary adjustments such as low fiber and light diet. If black stool or vomiting blood occurs, it may indicate gastrointestinal bleeding and requires emergency medical treatment and suspension of medication.

Precautions for Vadadustat

Scientific use of medication can significantly reduce treatment risks. The following are key precautions:

Drug interactions

Avoid taking iron-containing drugs such as polysaccharide iron complex at the same time, with an interval of 1 hour. When combined with simvastatin, the statin dose should be limited to less than 20 mg/day to avoid muscle toxicity. Monitor electrolyte balance when using diuretics such as furosemide.

Contraindicated groups

It is contraindicated in non-dialysis patients, patients with acute liver disease or cirrhosis. Patients who have had myocardial infarction or cerebral infarction within 3 months should avoid use to prevent the aggravation of blood clots.

Long-term monitoring requirements

Hb, iron metabolism indicators and liver function need to be measured regularly during treatment. If Hb does not reach the target within 24 weeks or the patient continues to rely on blood transfusion, the cause of the disease needs to be re-evaluated and the treatment plan adjusted.

Valdostat needs to be stored in a dark environment at 20–25°C. The original package contains a desiccant and must be sealed to prevent moisture after opening. The medicine is valid for 36 months. Do not continue to use it after the expiration date.